Oruka Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Menlo Park, CA
ORKA chart
What traders are saying about $ORKA
Latest postsOruka Therapeutics, Inc. news
- Oruka Therapeutics Faces Patent Expiry Risk That Could Accelerate Generic Competition and Pressure Future Revenues
TipRanks ·
- Phase 2 Psoriasis Results Could Be A Big Moment For Oruka Therapeutics Stock (ORKA)
Yahoo Finance ·
- Oruka Therapeutics Posts $0.63 Q3 GAAP Loss Per Share, Matching Estimates
TOKENPOST ·
- Oruka Therapeutics Rises After Fresh Clinical Update Keeps Late-Stage Psoriasis Program on Track
Quiver Quantitative ·
- Oruka Therapeutics (ORKA) Reports Phase 2 Progress, Is The Premium Valuation Already Priced In?
Simply Wall St ·
- Oruka Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- BTIG maintains Oruka Therapeutics at Buy, keeps price target at $151
TradingView ·
- Oruka Therapeutics (ORKA) Misses Q3 EPS by 3c
StreetInsider ·
- Oruka Therapeutics reports strong Q3 2026 resul...
Pluang ·
- Oruka Therapeutics 3Q 2026: EPS ($0.63) — 10-Q Summary
TradingView ·
- Oruka Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Yahoo Finance ·
- Six months after their last dose, 71% had clear skin in an Oruka study
Stock Titan ·
Oruka Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | $0 | $0 |
| Net income | -$105.4M | -$83.7M | -$5.3M | -$9.9M |
| Diluted EPS | – | $-3.87 | $-0.37 | $-0.69 |
| Total assets (year end) | $488.6M | $396.0M | $37.9M | $43.1M |
| Cash and equivalents (year end) | $46.9M | $61.6M | $37.4M | $42.4M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- 10-QQUARTERLY REPORT
- 8-KCURRENT REPORT
- 8-KCURRENT REPORT
- DEF 14APROXY STATEMENT
- 10-KANNUAL REPORT
About Oruka Therapeutics, Inc.
- Ticker
- ORKA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Menlo Park, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 907654
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
Frequently asked questions
What exchange is Oruka Therapeutics, Inc. listed on?
Oruka Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ORKA.
What industry is Oruka Therapeutics, Inc. in?
Oruka Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc.'s business address on file with the SEC is in Menlo Park, CA.
When does Oruka Therapeutics, Inc.'s fiscal year end?
Oruka Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Oruka Therapeutics, Inc. report?
Oruka Therapeutics, Inc. reported $0 in revenue for calendar year 2023, according to its SEC filings.